tirzepatide uses FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly New Tirzepatide Access and Pricing

In the SUSTAIN 7 trial, 0.5 mg/week semaglutide therapy considerably reduced the mean blood glucose levels, postprandial hyperglycemia across all meals, and mean 7-point self-measured blood glucose levels compared with the 0.75 mg/week dulaglutide therapy [14]

The semaglutide dosage chart provides visual reference for each titration step

Food and Drug Administration (FDA-i)

Additionally, its imperative to consult with your doctor to decide if tirzepatide is the right decision for you and to go over any questions you may have

Rising Adoption of GLP-1 Therapies for Obesity and Diabetes Management The key factor fuelling this market includes the fast-paced consumption of GLP-1 receptor agonist medicines since such drugs help to reduce appetite effectively, slow down digestion, and cause early satiety, resulting in lower consumption of food per meal